BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations

investors.com/news/technology/bridgebio-stock-bridgebio-earnings-q1-2025-attruby-vyndqel-amvuttra

BridgeBio's new heart drug — a rival to Pfizer's blockbuster Vyndaqel — smashed sales expectations in its first full quarter on the market.
The post BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations appeared first on Investor's Business Daily.

This story appeared on investors.com, 2025-04-29 20:01:38.
The Entire Business World on a Single Page. Free to Use →